Wall Street Turns Bullish on Crinetics and Fulcrum Therapeutics
Goldman Sachs and JPMorgan highlight new clinical data that strengthen the outlook for Crinetics and Fulcrum Therapeutics, citing clearer paths to success and upside potential.
/ 1661 items
#XY↓
REGENXBIO Shares Jump on Promising Duchenne Gene Therapy Results
REGENXBIO stock rises 8% after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
FDA Requests Additional Data on Stoke's Dravet Syndrome Treatment
Stoke Therapeutics continues discussions with FDA for expedited approval of zorevunersen for Dravet syndrome after regulators request more information on the epilepsy treatment.
PDS Biotech Submits Protocol Amendment for Faster Cancer Drug Approval
PDS Biotechnology updates Phase 3 trial protocol with FDA to potentially speed up approval of PDS0101 for HPV-related head and neck cancer treatment.
Amazon Pharmacy Now Offers Wegovy Weight-Loss Pill with Affordable Options
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.